SEC Comment Letter 0000000000-25-002610 to Bon Natural Life Ltd (BON)
Bon Natural Life Ltd
Date: March 10, 2025 · CIK: 0001816815 · Accession: 0000000000-25-002610
AI Filing Summary & Sentiment
File numbers found in text: 333-283333
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 10, 2025 Yongwei Hu Chief Executive Officer Bon Natural Life Limited C601, Gazelle Valley, No.69 Jinye Road Xi an Hi-tech Zone, Xi an, China Re: Bon Natural Life Limited Registration Statement on Form F-1 Response dated March 5, 2025 File No. 333-283333 Dear Yongwei Hu: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our March 4, 2025 letter. Amendment No. 3 to Registration Statement on Form S-1 General 1. We note your references throughout the prospectus to an alternative cashless exercise provision. The term cashless exercise is generally understood to allow a warrant holder to exercise a warrant without paying cash for the exercise price and reducing the number of shares receivable by the holder by an amount equal in value to an aggregate exercise price the holder would otherwise pay to exercise the warrant(s). In cashless exercises, it is expected that the warrant holder receives fewer shares than they would if they opted to pay the exercise price in cash. Please clarify your disclosure by removing the references to alternative cashless exercise and using the term zero exercise price exclusively. March 10, 2025 Page 2 Please contact Daniel Crawford at 202-551-7767 or Joe McCann at 202-551-6262 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cassi Olson, Esq. </TEXT> </DOCUMENT>